Table 1.
Current safety of the volunteer blood supply |
Success of surveillance and screening in dealing with emerging pathogens |
Inability of current technologies to inactivate all agents (small nonencapsulated viruses, spores, high titers of virus, and prions) |
Efficacy concerns |
No single method to treat all components |
Regulatory requirements |
Cost |